XCancer

Imaging of HER2-positive Cancer With Site-Specifically Labeled 89Zr-ss-Pertuzumab

Description:

The purpose of this study is to see whether 89Zr-ss-pertuzumab is safe in people with HER2+ cancer.

Sponsor:

Memorial Sloan Kettering Cancer Center

Phase:

Phase 1

Government Study Link:

NCT04692831 - Click here to see study on

ClinicalTrials.gov